Doxecitine + Doxribtimine bulk supplier for pharma manufacturers

Doxecitine + Doxribtimine 2g+2g Suppliers & Bulk Manufacturers

Available Forms: Oral Solution

Available Strengths: 2g+2g

Reference Brands: Kygevvi (USA)

Doxecitine (2′‑deoxycytidine) and doxribtimine (2′‑deoxythymidine) provide nucleosides to restore mitochondrial DNA synthesis in patients with TK2 deficiency. This helps improve mitochondrial function in muscle cells, reduce muscle weakness, delay disease progression, and improve survival.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Doxecitine + Doxribtimine — third party manufacturing & bulk supply

Doxecitine + Doxribtimine 2g+2g is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Doxecitine + Doxribtimine is supplied as Oral Solution — a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Doxecitine + Doxribtimine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Doxecitine + Doxribtimine →

Back to Listing

Frequently Asked Questions

This combination is used to treat Thymidine Kinase 2 Deficiency (TK2d), a rare, inherited mitochondrial disorder that leads to progressive muscle weakness, breathing problems, and mitochondrial DNA depletion. It is the first and currently only approved therapy targeting the underlying cause of TK2d, aiming to restore mitochondrial DNA replication and improve cell energy metabolism.

Doxecitine is a pyrimidine nucleoside — chemically deoxycytidine — and Doxribtimine is deoxythymidine (thymidine nucleoside). Together they supply deoxynucleosides needed for mitochondrial DNA synthesis. The formulation also contains inactive excipients that permit the preparation of an oral solution.

The trade name for this combination is Kygevvi.

Kygevvi is manufactured by UCB, Inc..

The generic names are doxecitine and doxribtimine.

The brand name is Kygevvi.

Kygevvi is produced by UCB, Inc. in regulated pharmaceutical manufacturing facilities and supplied under globally approved Good Manufacturing Practice (GMP) standards.